Fig. 1. Predicted pseudo-virus neutralization titer by days since full immunization (day 1 for mAbs, day 57 for vaccine) for ten randomly selected participants from the COVE immunogenicity subcohort (gold) and COV-2969 (green) trials.

The COVE lines use the measured Day 57 neutralization titer (red circle) with subsequent decay determined by a common slope estimated from independent data. Casirivimab + imdevimab mAb lines use concentration curves based on sex and weight and subsequently converted to neutralization titer. The curves start at day 8 days post full immunization (vaccine) or injection (mAb) and stop at the time of event or the end of follow-up.